Candida auris vs. Non-Candida auris Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality
Journal of Fungi · 24.07.2025 · 11 (8) · 552
DOI: 10.3390/jof11080552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 24.07.2025. Verfasst von Ezgi Gülten und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, Turkey. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background:Candida auris (now Candidozyma auris) is an emerging pathogen that causes nosocomial candidemia, particularly in intensive care unit (ICU) settings. Its high resistance rates, prolonged environmental persistence, and outbreak potential underscore the need for robust comparative studies with non-auris Candida species (NACS).
Methods
In this retrospective, case–control study, adult ICU patients with candidemia were enrolled between April 2022 and October 2024. Clinical data, risk factors, and mortality at 14, 30, and 90 days were compared between the C. auris and NACS groups. Univariate and multivariate logistic regression analyses were performed to identify mortality-associated factors.
Results
Of the 182 patients analyzed, candidemia due to C. auris was identified in 33 (18.1%) cases, while 149 (81.9%) cases involved NACS. Fluconazole resistance (p < 0.001), prior antifungal exposure (p = 0.003), urinary catheter use (p = 0.040), and the length of ICU stay before the onset of candidemia (p < 0.001) were significantly higher in the C. auris cases. However, mortality rates at 14, 30, and 90 days were similar between the groups (p = 0.331, 0.108, and 0.273, respectively). The Sequential Organ Failure Assessment score was the only consistent independent predictor of mortality at all time points. In the NACS cases, the Pitt Bacteremia Score and sepsis also predicted 30- and 90-day mortality. While late recurrence was more frequent in the cases of C. auris, early recurrence and other risk factors were similar between the groups. Conclusions:C. auris candidemia was associated with higher fluconazole resistance, prior antifungal use, longer ICU stay, more frequent urinary catheterization, and later recurrence than the NACS cases. However, the mortality rates at 14, 30, and 90 days were comparable. Outcomes were primarily influenced by illness severity rather than the infecting Candida species, highlighting the importance of timely therapy, stewardship, and infection control.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ankara University, 06230 Ankara, Turkey.
ORCID-Profile: Ezgi Gülten, Güle Çınar, Elif Mukime Sarıcaoğlu, İrem Akdemir, Afife Zeynep Yılmaz, Elif Hilal Saldere, Fügen Yörük
Zitieren
APA
Gülten, E., Çınar, G., Sarıcaoğlu, E. M., Akdemir, İ., Yılmaz, A. Z., Saldere, E. H., & Yörük, F. (2025). Candida auris vs. Non-Candida auris Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality. Journal of Fungi, 11(8), 552. https://doi.org/10.3390/jof11080552
Vancouver
Gülten E, Çınar G, Sarıcaoğlu EM, Akdemir İ, Yılmaz AZ, Saldere EH, et al. Candida auris vs. Non-Candida auris Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality. Journal of Fungi. 2025;11(8):552. doi:10.3390/jof11080552
BibTeX
@article{Glten2025,
author = {Gülten, Ezgi and Çınar, Güle and Sarıcaoğlu, Elif Mukime and Akdemir, İrem and Yılmaz, Afife Zeynep and Saldere, Elif Hilal and Yörük, Fügen},
title = {Candida auris vs. Non-Candida auris Candidemia in Critically Ill Patients: Clinical Outcomes, Risk Factors, and Mortality},
journal = {Journal of Fungi},
year = {2025},
volume = {11},
number = {8},
pages = {552},
doi = {10.3390/jof11080552}
}
EUVIMED